Does Lowering the Pressure Actually Help, or Only the Bundle It Came With: Blood Pressure Targets in Acute ICH
Two major trials tested the same aggressive blood pressure target in intracerebral hemorrhage and reached different-flavored answers, and a third that finally showed a real benefit did it by testing a whole bundle of interventions at once — leaving genuinely open how much of that benefit belongs to the pressure number itself.
P.D., a 67-year-old man who has driven a school bus route for eleven years and takes genuine pride in "never being the reason a kid's late," developed a sudden severe headache and left-sided weakness while parked at the bus lot before his afternoon route, noticed immediately by a colleague waiting nearby. He arrived at the emergency department within forty minutes, alert but with dense left hemiparesis, NIHSS 12, and a blood pressure of 210/118. He has hypertension, treated inconsistently on lisinopril — he admits to running out of refills "more than I should" — and no history of anticoagulant use or prior bleeding.
Noncontrast CT confirms a moderate right basal ganglia hemorrhage, roughly 20mL, without intraventricular extension, and no clear structural lesion (aneurysm or vascular malformation) to explain it beyond his longstanding, poorly controlled hypertension. His coagulation studies are normal and he takes no anticoagulant, so reversal isn't a factor in his management. The immediate question is how aggressively to lower his blood pressure. ATACH-2, a dedicated randomized trial, tested exactly this question — intensive lowering, target 110-139 systolic, against standard management, target 140-179 — and found no significant difference in functional outcome, with significantly more renal adverse events in the intensive arm. INTERACT2, an earlier trial with a similar comparison, found a nonsignificant trend toward benefit on its primary endpoint that reached significance only on a secondary ordinal-shift analysis. INTERACT3, the newest and largest of the three, took a different approach: rather than testing blood pressure lowering alone, it tested a bundled early care pathway — intensive BP lowering combined with glucose control, temperature control, and rapid anticoagulation reversal where applicable — against usual care, and found the bundle improved functional outcome. His own presentation, moderate-volume hemorrhage, severely elevated pressure, no anticoagulant to reverse, sits squarely inside the population all three trials enrolled, without a clean way to tell from his numbers alone which trial's design gives the more trustworthy answer to tonight's actual question.
On arrival, choosing tonight's blood pressure target
I'd manage him under the INTERACT3 bundle — intensive lowering as part of the full early-care pathway, target under 140 within the first hour, alongside glucose and temperature control. That's the newest and largest trial, and it showed real improvement in functional outcome, not a neutral or marginal result.
I'd slow down on that specific number, though. ATACH-2 tested intensive lowering in isolation — target 110-139 — against standard management and found no significant difference in outcome, plus significantly more renal adverse events in the intensive arm. That trial isolated the exact variable we're deciding on tonight and came back null. INTERACT3 tested a whole bundle at once; it can't tell us how much of its benefit actually came from the pressure number itself versus the glucose and temperature management alongside it.
I wouldn't override a dedicated null result with a differently-designed composite trial that wasn't built to isolate the same thing.
Both of those reads are fair, and I don't think this resolves cleanly tonight. I'd land in the middle: target 140-160, real reduction from his presenting 210/118 without chasing ATACH-2's more aggressive 110-139 range or its associated renal signal. His baseline renal function is normal, which gives some room, but I'd rather not test how much of that renal-safety signal was protocol-specific versus target-specific on him directly.
Agreed: nicardipine infusion titrated to a target systolic pressure of 140-160, reassessed against serial imaging and renal function over the following 24 hours. Glucose and temperature managed per standard supportive care alongside the pressure target, incorporating the parts of the INTERACT3 bundle the group found least contested.
Not agreed: the neurointensivist's preference for a more aggressive target under 140 specifically, following INTERACT3's own protocol more literally, remained a live, stated disagreement rather than something the moderate compromise actually resolved — the group proceeded with the middle target for tonight without anyone claiming the underlying evidentiary disagreement was settled.